Omeros (OMER) Income towards Parent Company (2010 - 2026)
Omeros (OMER) posted Income towards Parent Company of $4.8 million for Q1 2026, down 26.67% sequentially from $6.6 million in Q4 2025, and up 17.2% YoY from $4.1 million in Q1 2025.
Analysis
Omeros (OMER) Income towards Parent Company (2010 - 2026) Analysis & Trends
Omeros has reported Income towards Parent Company for 17 years, with the latest figure at $4.8 million in Q1 2026.
- Quarterly Income towards Parent Company rose 17.2% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 90.69% YoY) and the FY2025 annual result came in at $1.5 million, down 94.35% from the prior year.
- Income towards Parent Company declined to $4.8 million in Q1 2026 per OMER's latest filing, from $6.6 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $174.8 million in Q4 2022 and troughed at -$9.7 million in Q3 2025.
- A 5-year average of $18.7 million and a median of $6.6 million in 2025 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company surged 73.05% in 2022, then tumbled 298.2% in 2025.
- Over 5 years, Income towards Parent Company stood at $174.8 million in 2022, then sank by 82.71% to $30.2 million in 2023, then plunged by 82.85% to $5.2 million in 2024, then gained by 26.59% to $6.6 million in 2025, then retreated by 26.67% to $4.8 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $4.8 million, $6.6 million, and -$9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Omeros | 1.37 Bn | 1.37 Bn | 27.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.23 Mn |
| Mar 31, 2026 | 56.06 Mn |
| Dec 31, 2025 | -30.13 Mn |
| Sep 30, 2025 | -22.10 Mn |
| Jun 30, 2025 | -25.42 Mn |
| Mar 31, 2025 | -33.46 Mn |
| Dec 31, 2024 | -29.07 Mn |
| Sep 30, 2024 | -32.23 Mn |
| Jun 30, 2024 | -56.04 Mn |
| Mar 31, 2024 | -37.18 Mn |
| Dec 31, 2023 | -13.18 Mn |
| Sep 30, 2023 | -37.75 Mn |
| Jun 30, 2023 | -37.29 Mn |
| Mar 31, 2023 | -33.70 Mn |
| Dec 31, 2022 | -96.76 Mn |
| Sep 30, 2022 | -17.46 Mn |
| Jun 30, 2022 | -30.85 Mn |
| Mar 31, 2022 | -33.01 Mn |
| Dec 31, 2021 | -162.00 Mn |
| Sep 30, 2021 | -1.13 Mn |